Literature DB >> 16437131

Readministration of helper-dependent adenovirus to mouse lung.

D R Koehler1, B Martin, M Corey, D Palmer, P Ng, A K Tanswell, J Hu.   

Abstract

Adenovirus vectors (Ad) are widely used in gene therapy studies, including those aimed at treating cystic fibrosis lung disease. Various approaches have been investigated to blunt the host immune response to Ad, including development of helper-dependent (HD) Ad. The host cytotoxic T-cell response to HD-Ad is generally lower than to earlier-generation Ad. However, antibodies are formed which could inhibit the efficacy of HD-Ad readministration. In this first study of HD-Ad readministration to the lung, we found that a second administration of HD-Ad to mice was possible with minimal loss of transgene expression. In contrast, when first-generation (FG) Ad was administered initially, followed by HD-Ad or FG-Ad, transgene expression was reduced. Significantly lower concentrations of antibodies against Ad were found in lung lavage fluid and serum from mice that received two doses of HD-Ad (when the initial HD-Ad lacked a transgene), compared to mice that received FG-Ad followed by HD-Ad. These data suggest that readministration of HD-Ad for lung gene therapy may be feasible.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16437131     DOI: 10.1038/sj.gt.3302712

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  20 in total

Review 1.  Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors.

Authors:  N Brunetti-Pierri; P Ng
Journal:  Gene Ther       Date:  2008-02-21       Impact factor: 5.250

Review 2.  Gene therapy for ALI/ARDS.

Authors:  Xin Lin; David A Dean
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

3.  Pancreatic transduction by helper-dependent adenoviral vectors via intraductal delivery.

Authors:  Meritxell Morró; Joan Teichenne; Veronica Jimenez; Ramona Kratzer; Serena Marletta; Luca Maggioni; Cristina Mallol; Jesus Ruberte; Stefan Kochanek; Fatima Bosch; Eduard Ayuso
Journal:  Hum Gene Ther       Date:  2014-09       Impact factor: 5.695

4.  Induction of immunological tolerance to adenoviral vectors by using a novel dendritic cell-based strategy.

Authors:  Rahul Kushwah; Jordan R Oliver; Rongqi Duan; Li Zhang; Shaf Keshavjee; Jim Hu
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

5.  Vaccines within vaccines: the use of adenovirus types 4 and 7 as influenza vaccine vectors.

Authors:  Eric A Weaver
Journal:  Hum Vaccin Immunother       Date:  2013-11-26       Impact factor: 3.452

Review 6.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

7.  Lysophosphatidylcholine as an adjuvant for lentiviral vector mediated gene transfer to airway epithelium: effect of acyl chain length.

Authors:  Patricia Cmielewski; Don S Anson; David W Parsons
Journal:  Respir Res       Date:  2010-06-23

8.  Lentivirus vector can be readministered to nasal epithelia without blocking immune responses.

Authors:  Patrick L Sinn; Ariadna C Arias; Kim A Brogden; Paul B McCray
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

Review 9.  Progress and prospects: prospects of repeated pulmonary administration of viral vectors.

Authors:  P L Sinn; E R Burnight; P B McCray
Journal:  Gene Ther       Date:  2009-07-30       Impact factor: 5.250

Review 10.  Gene therapy for cystic fibrosis.

Authors:  Christian Mueller; Terence R Flotte
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.